cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/00002524
title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease

description: This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
DOI: 10.25934/00003004
title: A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis

description: The objective of this study is to assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.
DOI: 10.25934/00003009
title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis

description: This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).
DOI: 10.25934/00003014
title: A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

description: To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.
DOI: 10.25934/00003015
title: A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

description: The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.
DOI: 10.25934/00003052
title: A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis.

description: The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).
DOI: 10.25934/00003184
title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction and Maintenance of Clinical Remission in Chinese Patients With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein

description: This study will evaluate the efficacy and safety of adalimumab induction and maintenance treatment in subjects with moderately to severely active Crohn's disease.
DOI: 10.25934/00003275
title: Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Ulcerative Colitis

description: This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002 (Vedolizumab) in induction and maintenance therapy in Japanese patients with moderately or severely active ulcerative colitis.
DOI: 10.25934/00004734
title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis

description: The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).
DOI: 10.25934/00004736
title: A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis

description: The purpose of this study is to assess the safety and efficacy of golimumab administered subcutaneously (under the skin) injections in maintenance therapy.
DOI: 10.25934/00004737
title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis

description: The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with active ulcerative colitis (UC) (sores in the colon).
DOI: 10.25934/00004769
title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy

description: A medical research study in adult patients who have moderate to severe Crohn's disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO1275) is safe or not and to determine if the treatment will reduce the symptoms of Crohn's disease.
DOI: 10.25934/00004833
title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)

description: This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or could not tolerate at least one TNF-antagonist medications in the past (specifically, infliximab, adalimumab, or certolizumab pegol).
DOI: 10.25934/00004834
title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)

description: This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.
DOI: 10.25934/00004835
title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease

description: The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to treatment with intravenous ustekinumab in studies CNTO1275CRD3001 and CNTO1275CRD3002, compared to subcutaneously administered placebo.
DOI: 10.25934/00004847
title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects With Active Ulcerative Colitis

description: The purpose of this study is to evaluate the effectiveness and safety of infliximab in Chinese patients with active ulcerative colitis (swelling and ulceration of large intestine and rectum).
DOI: 10.25934/00004860
title: A Phase 3 Multicenter, Placebo-controlled, Double-blind, Randomized-withdrawal Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

description: The purpose of this study is to evaluate safety and effectiveness of golimumab in Japanese participants with moderately to severely active ulcerative colitis.
DOI: 10.25934/00005572
title: Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Subjects With Moderate or Severe Crohn's Disease

description: This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in Japanese participants with moderately or severely active Crohn's disease.
DOI: 10.3535/53g-et2-rlb
title: Geranium pusillum L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53g-fvh-397
title: Dryopteris filix-mas (L.) Schott

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53g-t2h-1a9
title: Juncus articulatus L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53g-zqd-nxa
title: Rumex crispus L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53h-8b5-8fp
title: Spergula arvensis subsp. sativa (Boenn.) Celak.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53h-dam-n50
title: Eleocharis uniglumis (Link) Schult.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53h-ev9-yl7
title: Stratiotes aloides L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53h-r1m-b19
title: Alchemilla baltica Sam. ex Juz.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53g-ntz-1wn
title: Elymus repens (L.) Gould

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53h-r48-58a
title: Woodsia ilvensis (L.) R. Br.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53h-tc0-n0x
title: Vicia tetrasperma (L.) Schreb.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.5281/zenodo.17993961
title: Raw data associated with the manuscript "Pressure-Induced Band-Gap Evolution Governed by Competing Orbital Coupling and Lattice Anharmonicity in Cu/Ag-Stuffed Zinc-Blende X₂YZ Compounds"
DOI: 10.5281/zenodo.17993962
title: Raw data associated with the manuscript "Pressure-Induced Band-Gap Evolution Governed by Competing Orbital Coupling and Lattice Anharmonicity in Cu/Ag-Stuffed Zinc-Blende X₂YZ Compounds"
DOI: 10.3535/53h-v44-kc3
title: Deschampsia cespitosa (L.) P.Beauv.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/53h-x0v-bey
title: Carex bigelowii subsp. bigelowii

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.7483/opendata.cms.rqoj.kp6o
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-2600_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.15468/dl.4cubsx
title: Occurrence Download

description: A dataset containing 348797 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is ISL",
 "Month is one of (June, July)",
 "OccurrenceStatus is Present",
 "TaxonKey is Aves"
 ]
}

 The dataset includes 348797 records from 60 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0000162-250117103327516/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.7483/opendata.cms.krh7.uhaj
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-2800_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM
DOI: 10.7483/opendata.cms.3ly0.7zvn
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-2800_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.7483/opendata.cms.o9c2.5ge7
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-300_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM
DOI: 10.7483/opendata.cms.bzcn.w7yj
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-300_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.7483/opendata.cms.m1kk.cvyp
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-400_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM
DOI: 10.17632/vp95thgty8.1
title: LINF_360057200

description: mitochondrial RNA binding complex 1 subunit (MRB10130) | RESC8
Leishmania infantum (strain JPCM5)
DOI: 10.7483/opendata.cms.ucwm.5igp
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-400_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.17632/4mcnydgsyn.1
title: LINF_360057600

description: Kinetoplast polyadenylation factor 4 | KPAF4
Leishmania infantum (strain JPCM5)
DOI: 10.7483/opendata.cms.7l5d.s5wo
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-500_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM
DOI: 10.17632/grwf69pf3c.1
title: LINF_180008800

description: Hypothetical protein - conserved; Leishmania infantum (strain JPCM5)
DOI: 10.17632/85ch78gk6r
title: LINF_170020300

description: Hypothetical protein - conserved; Leishmania infantum (strain JPCM5)
DOI: 10.17632/85ch78gk6r.1
title: LINF_170020300

description: Hypothetical protein - conserved; Leishmania infantum (strain JPCM5)
DOI: 10.7483/opendata.cms.evqn.xt7u
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-500_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.7483/opendata.cms.eafn.gy4f
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-600_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM
DOI: 10.17632/nvp49jbmb6.1
title: LINF_360057900

description: Leucine-rich repeat domain containing protein
Leishmania infantum (strain JPCM5)
DOI: 10.17632/c4jhckhhps.1
title: Coded Data for Replication of Dynamic Analyses of Qualitative Evidence via GRATIS

description: This is a dataset used in the paper titled "Graphical Retrieval and Analysis of Temporal Information Systems (GRATIS): An Integrative Mixed Methodology and Open-Access Software to Analyze the (Non-)Linear Chronological Evolution of Information Embedded in Textual/Qualitative Data"
This study has been accepted at the Journal of Mixed Methods Research and it is currently in production.
DOI: 10.7483/opendata.cms.79t2.9rq0
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-600_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.15468/dl.n27cja
title: Occurrence Download

description: A dataset containing 14452 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Scarus ghobban Forsskål, 1775"
 ]
}

 The dataset includes 14452 records from 202 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0000173-250117103327516/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17632/vxpkzxhgng.1
title: LDHU3_17.0120

description: Elongation factor 1-alpha; Leishmania donovani (HU3 strain)
DOI: 10.17632/5s2c2jkn94
title: LDHU3_17.0110

description: Elongation factor 1-alpha; Leishmania donovani (HU3 strain)
DOI: 10.17632/5s2c2jkn94.1
title: LDHU3_17.0110

description: Elongation factor 1-alpha; Leishmania donovani (HU3 strain)
DOI: 10.7483/opendata.cms.cvrt.dmtm
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-60_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM
DOI: 10.7483/opendata.cms.asq2.104l
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-60_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.17632/p58cymdnhn
title: LDHU3_17.0140

description: Elongation factor 1-alpha; Leishmania donovani (HU3 strain)
DOI: 10.17632/p58cymdnhn.1
title: LDHU3_17.0140

description: Elongation factor 1-alpha; Leishmania donovani (HU3 strain)
DOI: 10.7483/opendata.cms.3uxa.mg1g
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-700_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM
DOI: 10.17632/pcjs75ky4z.1
title: LINF_270007500

description: kinetoplast-associated protein-like protein; Leishmania infantum (strain JPCM5)
DOI: 10.7483/opendata.cms.mrss.nvam
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-700_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.17632/7v6yg5rd4t.1
title: LDHU3_05.0320

description: Protein of unknown function – conserved; Leishmania donovani (HU3 strain)
DOI: 10.6084/m9.figshare.28228676
title: the plastisphere in coastal salt marshes

description: Microplastics (MPs) introduce a unique ecological niche for microorganisms, termed the “plastisphere”. Coastal salt marshes are critical blue-carbon systems and MP sinks. However, the impacts of the plastisphere on major elemental cycling in coastal salt marshes remain poorly understood. To answer this important question, we conducted a 1-year field experiment in both the intertidal (Spartina alterniflora, SA) and supratidal (Phragmites australis, PA) zones of Yancheng salt marshes in China and investigated the dynamics using metagenomics.
DOI: 10.6084/m9.figshare.28228676.v1
title: the plastisphere in coastal salt marshes

description: Microplastics (MPs) introduce a unique ecological niche for microorganisms, termed the “plastisphere”. Coastal salt marshes are critical blue-carbon systems and MP sinks. However, the impacts of the plastisphere on major elemental cycling in coastal salt marshes remain poorly understood. To answer this important question, we conducted a 1-year field experiment in both the intertidal (Spartina alterniflora, SA) and supratidal (Phragmites australis, PA) zones of Yancheng salt marshes in China and investigated the dynamics using metagenomics.
DOI: 10.17632/3vsmmhhrtp.1
title: Codes for the article “Predicting your children's returns to schooling”, Portuguese Economic Journal, version for revise and resubmit.

description: These codes help to replicate all the empirical analysis in the article: “Predicting your children's returns to schooling”, Portuguese Economic Journal, revise and resubmit. It helps to replicate all the main results tables: Tables 6, 7, 8, 9, 10, 11, A.3, A.4, A.5, A.6 and A.7. It also includes the GMM estimator function used to obtain the results.

This research used The Beginning School Study, 1982--2002 (Log# 01293) dataset (made accessible in 2004, numeric data files). These data were collected by Karl L. Alexander and Doris R. Entwisle and are available through the Henry A. Murray Research Archive of the Institute for Quantitative SocialScience at Harvard University, Cambridge, Massachusetts (Producer and Distributor).
DOI: 10.7483/opendata.cms.tro0.teaa
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-70_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM
DOI: 10.7483/opendata.cms.9mju.5r1o
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-70_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.17632/5sktkmg8x9.1
title: 2022 Agua Salud LMER Code RStudio

description: This is an RStudio script for a linear mixed effects model analysis using lmer. This linear mixed effects model was constructed to analyze the relative impacts of soil temperature, soil moisture, forest floor mass and soil organic C on soil CO2 fluxes (see dataset entitled 2022 Agua Salud CO2 Fluxes - Raw Data). First, a full mixed effects model was constructed using soil temperature (T), soil moisture (Moist), forest floor mass (Litter), and soil organic C (SOC) and their two-level interactions as fixed effects with Site as a random effect. First, 
a manual backward stepwise regression was performed based on the Akaike information criterion (AIC), sequentially eliminating highest-level non-significant terms (p-value &gt;0.1) until arriving at the most parsimonious model with only significant main effects and interaction terms. Next, the coefficients or parameter estimates for each term were determined using summary(model) for the final model. P-values for each main effect or interaction term were determined using the Likelihood Ratio Test.
DOI: 10.7483/opendata.cms.3k0g.3evv
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-800_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM
DOI: 10.17632/83ffn959js.1
title: Structural data from East Spanish-Portuguese Central System

description: This dataset includes a collection of individual measurements of bedding, foliation and fold axes in the East Spanish-Portuguese Central System, located in Central Iberia (Spain). Data were collected in 2021 and 2022. Planar and linear data are divided into several groups, depending on the type and time of formation. Bedding is referred to as S0, but the data are divided into strata formed during the Variscan cycle (crystalline basement) and strata formed during the Alpine cycle (cover). Foliation measurements refer to the orientation of the local main foliation formed during Variscan deformation and metamorphism. Fold axes are divided into those related to structures formed during the Variscan Orogeny and those formed during the Alpine Orogeny.
Plane measurements are given as dip direction and dip, while line measurements are given as plunge and trend. The structural dataset includes UTM coordinates (Zone 29, European Datum 1950) indicating the location of individual measurements.
DOI: 10.7483/opendata.cms.3pnj.8wwa
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-800_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16NanoAODv9-106X_mcRun2_asymptotic_v17-v1/NANOAODSIM
DOI: 10.17632/ctb8brksnm.1
title: Efficacy and Safety of Oral Ritlecitinib for the Treatment of Active Nonsegmental Vitiligo: A Randomized Phase 2b Clinical Trial - Supplementary Material

description: Background
Vitiligo is a chronic autoimmune disorder characterized by depigmented patches of the skin.

Objective
To evaluate the efficacy and safety of ritlecitinib, an oral JAK3/TEC inhibitor, in patients with active nonsegmental vitiligo (NSV) in a phase 2b trial (NCT03715829).

Methods
Patients were randomized to once-daily oral ritlecitinib ± 4-week loading dose (200/50 mg, 100/50 mg, 30 mg, or 10 mg) or placebo for 24 weeks (dose-ranging period). Patients subsequently received ritlecitinib 200/50 mg daily in a 24-week extension period. The primary efficacy endpoint was percent change from baseline (%CFB) in Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24. 

Results
364 patients were treated in the dose-ranging period. Significant differences from placebo in %CFB in F-VASI were observed for the ritlecitinib 50 mg groups with (-21.2 vs 2.1, P&lt;0.001) or without (-18.5 vs 2.1, P&lt;0.001) a loading dose and ritlecitinib 30 mg group (-14.6 vs 2.1, P=0.01). Accelerated improvement was observed after treatment with ritlecitinib 200/50 mg in the extension period (n=187). No dose-dependent trends in treatment-emergent or serious adverse events were observed across the 48-week treatment.

Limitations
Patients with stable vitiligo only were excluded.

Conclusions
Oral ritlecitinib was effective and well-tolerated over 48 weeks in patients with active NSV.
DOI: 10.7483/opendata.cms.vzsl.so1e
title: /NMSSM_XToYHTo2G2WTo2G4Q_MX-4000_MY-80_TuneCP5_13TeV-madgraph-pythia8/RunIISummer20UL16MiniAODv2-106X_mcRun2_asymptotic_v17-v2/MINIAODSIM